2023 World Conference on Lung Cancer (Posters)-EP11.01. Study on Biomarkers for Predictive the Clinical Efficacy of Non-small Cell Lung Cancer Immunotherapy

EP11.01. Study on Biomarkers for Predictive the Clinical Efficacy of Non-small Cell Lung Cancer Immunotherapy - PDF(Slides)

Back to course

Pdf Summary

Dr. Tian Yingxuan, a professor of Internal medicine at Xi'an Medical University and the Chief physician of the Department of Respiratory Medicine for the Elderly at Shaanxi Provincial People's Hospital in China, conducted a study on identifying biomarkers that can predict the clinical efficacy of immunotherapy for non-small cell lung cancer (NSCLC).<br /><br />The study focused on Tregs, which are immunosuppressive cells that play a crucial role in immune regulation and tumor immune escape. The researchers observed the levels of Tregs and other T lymphocyte subsets in the tumor microenvironment, lymph nodes, and peripheral blood of NSCLC patients before and after immunotherapy.<br /><br />The results showed that the application of immune checkpoint inhibitors (ICIs) stimulated the proliferation of effector T lymphocytes by releasing some of the inhibitory functions of Tregs. Therefore, monitoring peripheral blood immune markers before and after immunotherapy has clinical application value.<br /><br />The study also found that baseline levels of Tregs were an independent predictor of better prognosis in NSCLC patients undergoing immunotherapy. Furthermore, increased CD3 and CD4 T lymphocyte counts after immunotherapy were associated with a better prognosis.<br /><br />Additionally, the researchers identified other factors that influenced the progression of immunotherapy in NSCLC patients, including clinical stage and performance status score.<br /><br />In conclusion, Dr. Tian Yingxuan's study suggests that monitoring the levels of Tregs and other T lymphocyte subsets in peripheral blood can help predict the clinical efficacy of immunotherapy in NSCLC patients. Baseline Tregs levels, clinical stage, and performance status score were found to be independent influencing factors on treatment progression and prognosis. Increased CD3 and CD4 T lymphocyte counts after immunotherapy were associated with better outcomes.

Asset Subtitle

Tong Cui

Meta Tag

Speaker Tong Cui

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

Tian Yingxuan

Internal medicine

Immunotherapy

NSCLC

Tregs

Peripheral blood

Clinical efficacy

Prognosis

CD3

CD4